Navigation Links
U.S. Census Bureau Daily Feature for November 5
Date:11/4/2012

WASHINGTON, Nov. 5, 2012 /PRNewswire-USNewswire/ --  Following is the daily "Profile America" feature from the U.S. Census Bureau:

(Logo: http://photos.prnewswire.com/prnh/20110428/DC91889LOGO)

MONDAY, NOVEMBER 5: FIRST U.S. ANTIBIOTIC

Profile America — Monday, November 5th.  This year's Nobel prizes were announced last month, and the award ceremonies will be held in Stockholm, Sweden and Oslo, Norway next month.  In 1952, the prize for medicine was awarded for the discovery of the first antibiotic produced in the U.S. — streptomycin.  The breakthrough medicine was developed by a Ukrainian immigrant, Dr. Selman Waksman, and four of his students at Rutgers University in New Jersey in 1944.  It went into production later that year and proved to be the first antibiotic treatment for tuberculosis.  Making antibiotics is now an $11.3 billion a year business.  You can find current data on the country's economy — on the go — by downloading the new "America's Economy" mobile application at <www.census.gov/mobile>.

Sources:
Kane's Famous First Facts, 4998
2007 Economic Census, NAICS 325411

Profile America is produced by the Center for New Media and Promotions of the U.S. Census Bureau. These daily features are available as produced segments, ready to air, on a monthly CD or on the Internet at <http://www.census.gov> (look for "Multimedia Gallery" by the "Newsroom" button). 


'/>"/>
SOURCE U.S. Census Bureau
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
2. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
3. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
4. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
5. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
6. Medical Device Daily Wins Prestigious SIPA Award for Outstanding Business Journalism
7. Daily Cocoa Flavanol Consumption Shown to Improve Cognitive Function in Older Adults
8. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
11. Medical Device Daily releases Med-Tech on a Mission: Strategies to Drive Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories Ltd., ... active pharmaceutical ingredients (APIs), complex intermediates and ... in 85 countries, today announced financial results for ... ended June 30, 2014. "Neuland,s results ... flow re-prioritization to accommodate certain customer needs, and ...
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
(Date:8/1/2014)... On Monday, June 30th, the Quirk ... in San Francisco, CA. Now in its fourth year, ... Union Square hotel. , “We are excited about returning ... with ACA compliance issues,” Quirk Healthcare Foundation Executive Director, ... attendees guidance with NextGen implementation and use, electronic records ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... Oxford Gene Technology (OGT) is ... products include CytoSure heamatological cancer +SNP Array, CytoSure ... UPD array, CytoSure ISCA sample tracking spike-ins and ... such as targeted sequencing services, SureSeq Solid Tumour ... expression analysis, cytosure services and aCGH for CNV ...
Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... change your genes, say researchers after success in a ... McGill University in Montreal have found that nutrients // ... certain genes in rodents, reports science portal EurekAlert., ... a two-year-old study, which showed that the activity of ...
... for losing teeth as is generally known, but there ... said study author Dr. Khalaf F. Al-Shammari, of Kuwait ... educating the public about these factors that appear to ... increased attention to avoiding such factors.' Al-Shammari and colleagues ...
... first Phase III study involving the use of Actemra ... it is superior to conventional treatment modality that uses ... destruction. It has also been found to provide symptomatic ... arthritis is a debilitating autoimmune disease in which the ...
... Recent research conducted at the Ohio State University shows ... of cancer deaths involves the loss of an essential ... muscular // dystrophy. , ,The study findings, which ... Cell, show that muscle cells lose significant amounts of ...
... Thousands of patients in the United Kingdom may be at ... A poll ,conducted by a team of researchers randomly on ... of their // patients were overdosing on vitamins and remained ... , ,A large number of patients were ignorant about ...
... loss of virginity affects men and women across the spectrum is ... First Sexual Experiences. This is the first book of its kind ... the most important events in life. We all read and hear ... sex, but it doesn't tell us what losing their virginity means ...
Cached Medicine News:Health News:Food Habits Could Change Your Genes 2Health News:Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis 2Health News:Loss Of Dystrophin: Common Thread In Cancer And MS Muscle Wasting 2Health News:Vitamin Abuse Syndrome In the UK 2
... DeepLight Glaucoma Treatment System will ... effective glaucoma treatments through the ... Micro-Shunt (GMS) and DeepLight 790 ... use the eye's natural pressure ...
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee...
The Regency family of pacemakers offers advanced, easy-to-use rate-responsive and nonrate-responsive devices....
... Identity ADx pacemaker family, which ... pacemaker, provides clinicians with the ... including the revolutionary AF Suppression™ ... U.S. commercially approved algorithm designed ...
Medicine Products: